PROSPECTIVE, RANDOMIZED SINGLE-BLIND STUDY TO EVALUATE THE REVERSAL OF SOFT TISSUE AND PULPAL ANESTHESIA USING PHENTOLAMINE MESYLATE (ORAVERSETM)

PROSPECTIVE, RANDOMIZED SINGLE-BLIND STUDY TO EVALUATE THE REVERSAL OF SOFT TISSUE AND PULPAL ANESTHESIA USING PHENTOLAMINE MESYLATE (ORAVERSETM)

Bibliographic Details
Main Author:	Elmore, Spencer J.
Language:	English
Published:	The Ohio State University / OhioLINK 2011
Subjects:	Dentistry Local anesthetic reversal Phentolamine mesylate OraVerse
Online Access:	http://rave.ohiolink.edu/etdc/view?acc_num=osu1316625279

Similar Items

Phentolamine mesylate: It′s role as a reversal agent for unwarranted prolonged local analgesia
by: Harpreet Singh Grover, et al.
Published: (2015-01-01)

Effect of phentolamine mesylate on duration of soft tissue local anesthesia in children
by: Nosrat Nourbakhsh, et al.
Published: (2012-01-01)

Use of Phentolamine Mesylate in Implant Surgery: Analysis of Adverse Effects and Haemodynamic Changes
by: Clara Vintanel-Moreno, et al.
Published: (2021-08-01)

Intravenous Regional Block with Phentolamine in the Treatment of Complex regional Pain Syndrome
by: Asadollah Saadat Niaki, et al.
Published: (2011-08-01)

Intravenous Regional Block with Phentolamine in the Treatment of Complex Regional Pain Syndrome
by: Hooshang Shahriyari, et al.
Published: (2011-08-01)

Arterial relaxation is coupled to inhibition of mitochondrial fission in arterial smooth muscle cells: comparison of vasorelaxant effects of verapamil and phentolamine
by: Jing Jin, et al.
Published: (2017-05-01)

Breaking the Syllabic-accentual Monotony
by: Mihhail Lotman
Published: (2015-12-01)

Lisdexamfetamine Toxicity with Delayed Hypertensive Emergency
by: Rachel Schult, et al.
Published: (2017-12-01)

Achieving pulpal anesthesia with a topical anesthetic paste
by: Bradley Carn, et al.
Published: (2015-01-01)

Commentary on “time-dependent selected reaction monitoring-based GC-MS/MS method for estimation of genotoxic impurities in a new antibacterial agent: alalevonadifloxin mesylate”
by: D. J. Snodin, et al.
Published: (2020-11-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
by: Malkan Umit Y., et al.
Published: (2018-12-01)

Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate
by: Abdul Ahad, et al.
Published: (2017-11-01)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
by: Yuan P, et al.
Published: (2021-02-01)

Easy and direct conversion of tosylates and mesylates into nitroalkanes
by: Alessandro Palmieri, et al.
Published: (2013-03-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Ants Oras and the Analysis of Early Modern English Dramatic Verse
by: MacDonald P. Jackson
Published: (2015-12-01)

The Effects of Eprosartan Mesylate and Lercanidipine on Reducing Microalbuminuria in Patients with Nephropathy due to Type 2 Diabetes
by: Botir T. Daminov, PhD, ScD, et al.
Published: (2013-06-01)

Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate
by: Pei L, et al.
Published: (2020-02-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
by: Huda A Al-Taee, et al.
Published: (2020-01-01)

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate
by: Ikhwan Rinaldi, et al.
Published: (2020-09-01)

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
by: Toru Hifumi, et al.
Published: (2020-08-01)

Gemifloxacin mesylate: UV spectrophotometric method for quantitative determination using experimental design for robustness
by: Clésio Soldateli Paim, et al.
Published: (2012-01-01)

Nafamostat Mesylate Improved Survival Outcomes of Sepsis Patients Who Underwent Blood Purification: A Nationwide Registry Study in Japan
by: Hiroshi Kamijo, et al.
Published: (2020-08-01)

A Survey of the Usage of Topical Anesthesia Among Dentist
by: Shults, Lawrence
Published: (2010)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
by: Vijay Gandhi Linga, et al.
Published: (2014-01-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01)

Influences of gabexate mesylate and ulinastatin on immune function, hemorheology and intestinal mucosal function of pancreatitic patients
by: Xiao-Song Mu, et al.
Published: (2016-12-01)

A rare case of eye complications of gastric stromal tumor treatment using imatinib mesylate
by: E. B. Myakoshina, et al.
Published: (2020-09-01)

In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery
by: Xu H, et al.
Published: (2021-02-01)

Effects of Imatinib Mesylate in Mouse Models of Multiple Sclerosis and In vitro Determinants
by: Gholamreza Azizi, et al.
Published: (2014-06-01)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
by: Ol'ga Veniaminovna Stakhina, et al.
Published: (2010-02-01)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
by: Ruth Gauden, et al.
Published: (2011-04-01)

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy
by: Ćojbašić Irena, et al.
Published: (2010-01-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)